Thousands of cancer patients enrolled in massive immunotherapy observation study

NCT ID NCT04766515

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in everyday practice, beyond the controlled conditions of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immune checkpoint inhibitors
What this could lead to: If successful, this study could provide doctors with better insights into which patients benefit most from immunotherapy in everyday practice.
What could go wrong: As an observational study, it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.